manilatimes

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical's DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- -Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared to DES- -Significantly lower ...
Mena FN

Late-Breaking Data Demonstrate Significant Clinical Advantage of Elixir Medical’s DynamX Bioadaptor Over Standard of Care Drug-Eluting Stent at Two Years

(MENAFN- Iris Media Press Services) Dubai, UAE; May 17, 2024 – Elixir Medical, a developer of transformative technologies to treat cardiovascular and peripheral disease, announced two-year results ...
manilatimes

EuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent

EuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent in Long-Term Follow-Up, Including Reduction in Cardiovascular Death Paris, France ...
Zawya

Clinical data demonstrates DynamX Bioadaptor restores vessel motion and function

Dubai, UAE: – Elixir Medical, a developer of breakthrough cardiovascular technologies with a strong presence in the Middle East market, today announced that the large international randomized ...
Business Wire

Elixir Medical Announces Outstanding 24-month Data for DynamX Coronary Bioadaptor System, Demonstrating Strong Safety With No Target Lesion Revascularization, Myocardial ...

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor ...